These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 11391856)

  • 21. Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice.
    Veltkamp SA; Pluim D; van Tellingen O; Beijnen JH; Schellens JH
    Drug Metab Dispos; 2008 Aug; 36(8):1606-15. PubMed ID: 18490432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pilot Study to Predict Pharmacokinetics of a Therapeutic Gemcitabine Dose From a Microdose.
    Van Nuland M; Rosing H; Thijssen B; Burgers JA; Huitema ADR; Marchetti S; Schellens JHM; Beijnen JH
    Clin Pharmacol Drug Dev; 2020 Nov; 9(8):929-937. PubMed ID: 31970932
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic function.
    Felici A; Di Segni S; Milella M; Colantonio S; Sperduti I; Nuvoli B; Contestabile M; Sacconi A; Zaratti M; Citro G; Cognetti F
    Clin Pharmacokinet; 2009; 48(2):131-41. PubMed ID: 19271785
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simultaneous determination of gemcitabine and its metabolite in human plasma by high-performance liquid chromatography.
    Yilmaz B; Kadioğlu YY; Aksoy Y
    J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Jul; 791(1-2):103-9. PubMed ID: 12798170
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Measurement of the anti-cancer agent gemcitabine in human plasma by high-performance liquid chromatography.
    Keith B; Xu Y; Grem JL
    J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Feb; 785(1):65-72. PubMed ID: 12535839
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours.
    Khatri A; Williams BW; Fisher J; Brundage RC; Gurvich VJ; Lis LG; Skubitz KM; Dudek AZ; Greeno EW; Kratzke RA; Lamba JK; Kirstein MN
    Br J Cancer; 2014 Jan; 110(2):304-12. PubMed ID: 24300978
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study.
    Laufer M; Ramalingam S; Schoenberg MP; Haisfield-Wolf ME; Zuhowski EG; Trueheart IN; Eisenberger MA; Nativ O; Egorin MJ
    J Clin Oncol; 2003 Feb; 21(4):697-703. PubMed ID: 12586808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates.
    Neville K; Parise RA; Thompson P; Aleksic A; Egorin MJ; Balis FM; McGuffey L; McCully C; Berg SL; Blaney SM
    Clin Cancer Res; 2004 Apr; 10(7):2525-9. PubMed ID: 15073132
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gemcitabine and epirubicin plasma concentration-related excretion in saliva in patients with non-small cell lung cancer.
    Maring JG; Wachters FM; Maurer M; Uges DR; de Vries EG; Groen HJ
    Ther Drug Monit; 2010 Jun; 32(3):364-8. PubMed ID: 20335827
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Population pharmacokinetics of gemcitabine applied to personalize the dosage used in cancer patients].
    Ramón-López A; Escudero-Ortiz V; Duart-Duart MJ; Pérez-Ruixo JJ; Valenzuela B
    Farm Hosp; 2012; 36(4):194-206. PubMed ID: 22078546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. No evidence of gemcitabine accumulation during weekly administration.
    de Lange SM; van der Born K; Kroep JR; Jensen HA; Pfeiffer P; Cleverly A; van Groeningen CJ; Peters GJ
    Eur J Clin Pharmacol; 2005 Dec; 61(11):843-9. PubMed ID: 16283278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determination of gemcitabine and its metabolite in extracellular fluid of rat brain tumor by ultra performance liquid chromatography-tandem mass spectrometry using microdialysis sampling after intralesional chemotherapy.
    Sun Y; Tang D; Chen H; Zhang F; Fan B; Zhang B; Fang S; Lu Q; Wei Y; Yin J; Yin X
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Mar; 919-920():10-9. PubMed ID: 23396113
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-performance liquid chromatographic method for the determination of gemcitabine and 2',2'-difluorodeoxyuridine in plasma and tissue culture media.
    Kirstein MN; Hassan I; Guire DE; Weller DR; Dagit JW; Fisher JE; Remmel RP
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 May; 835(1-2):136-42. PubMed ID: 16584929
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and cerebrospinal fluid penetration of CI-994 (N-acetyldinaline) in the nonhuman primate.
    Riva L; Blaney SM; Dauser R; Nuchtern JG; Durfee J; McGuffey L; Berg SL
    Clin Cancer Res; 2000 Mar; 6(3):994-7. PubMed ID: 10741726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer.
    Fogli S; Danesi R; De Braud F; De Pas T; Curigliano G; Giovannetti G; Del Tacca M
    Ann Oncol; 2001 Nov; 12(11):1553-9. PubMed ID: 11822754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous bolus dosing and its in vitro pharmacodynamics.
    Freise KJ; Martín-Jiménez T
    J Vet Pharmacol Ther; 2006 Apr; 29(2):137-45. PubMed ID: 16515668
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of infusion method on gemcitabine pharmacokinetics: a controlled randomized multicenter trial.
    Simon N; Romano O; Michel P; Pinçon C; Vasseur M; Lemahieu N; Barthélémy C; Hebbar M; Décaudin B; Odou P
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):865-71. PubMed ID: 26193987
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of intraperitoneal gemcitabine in a rat model.
    Pestieau SR; Stuart OA; Chang D; Jacquet P; Sugarbaker PH
    Tumori; 1998; 84(6):706-11. PubMed ID: 10080682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simultaneous determination of gemcitabine prodrug, gemcitabine and its major metabolite 2', 2'-difluorodeoxyuridine in rat plasma by UFLC-MS/MS.
    Sun Y; Zhen L; Peng Y; Wang J; Fei F; Aa L; Jiang W; Pei X; Lu L; Liu J; Wang G; Hao K
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 May; 1084():4-13. PubMed ID: 29558739
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic study to optimize the intravesical administration of gemcitabine.
    Gontero P; Cattel L; Paone TC; Milla P; Berta G; Fiorito C; Carbone F; Medana C; Tizzani A
    BJU Int; 2010 Dec; 106(11):1652-6. PubMed ID: 20590553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.